On Monday, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for Monogram Technologies Inc.’s (NASDAQ:MGRM) Monogram mBôs TKA System. Ben Sexson, Monogram’s Chief Executive Officer, ...
"The Middle East, and the Gulf region in particular, is ready for MBOs. With increasing pressure on family-owned businesses and governments to thrive in the global economy, private equity vendors may ...
FDA Decision is Expected Within 90 Days of Initial Submission; However, the Process May be Paused if Additional Information is Requested AUSTIN, TX / ACCESSWIRE / August 8, 2024 / Monogram ...
On February 26, 2025, Monogram (NASDAQ:MGRM) announced an update regarding its 510(k) premarket filing submission to the FDA for the company's mBôs TKA System. The company stated it had completed all ...
Company to Conduct Clinical Trial to Produce Additional Information Within 180 Days AUSTIN, TX / ACCESSWIRE / October 2, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), ...
This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results